ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
42 announcements
AstraZeneca Pharma India appointed Ms. Shilpa Divekar Nirula as Chairperson for five years. BSR & Co. LLP was also appointed as Statutory Auditor for a 60-month term.
AstraZeneca Pharma India recommended a final dividend of ₹24 per equity share for FY 2025-26. The payout is subject to shareholder approval at the August AGM.
AstraZeneca Pharma India reported FY 2025-26 revenue of ₹2,275.58 Crore, marking 33% growth. The Company secured 11 regulatory approvals, reinforcing leadership in oncology and biopharmaceuticals.
AstraZeneca Pharma India Ltd reported revenue from operations of ₹578.6 Cr (+20.4% YoY) and net profit of ₹44.9 Cr (-22.9% YoY) for Q4 FY26.
AstraZeneca Pharma India reported ₹2,275.58 Crore total income for FY25-26, marking 33% growth. The board recommended a ₹36 per share dividend, reflecting strong performance.
AstraZeneca Pharma India received CDSCO approval to market Calquence for treating previously untreated mantle cell lymphoma. This expands the drug's Indian market indications for adult patients.
AstraZeneca Pharma India updated its list of Key Managerial Personnel authorized to determine event materiality. This administrative disclosure ensures compliance with SEBI Listing Obligations.
AstraZeneca Pharma India scheduled a board meeting for May 26, 2026. Directors will consider FY26 audited financial results and potential dividend recommendations for shareholders.
AstraZeneca Pharma India's shareholders approved shifting its Registered Office from Karnataka to Maharashtra. This relocation follows a special resolution and remains subject to regulatory approvals.
AstraZeneca Pharma India announced shareholders approved shifting its registered office to Maharashtra via postal ballot. The special resolution passed with a 99.99% majority vote.
AstraZeneca Pharma India Ltd has issued a postal ballot notice to shift its registered office from Karnataka to Maharashtra. The move aims to enhance administrative efficiency and strengthen the company's footprint in Mumbai. Shareholders can vote electronically from April 12 to May 11, 2026.
AstraZeneca Pharma India Ltd received CDSCO approval to import and market Calquence (Acalabrutinib 100mg) for treating previously untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma. This additional indication expands the drug's therapeutic reach in the Indian market, subject to final statutory approvals.